Spinal Muscular Atrophy Clinical Trials
Spinal Muscular Atrophy (SMA) is a rare, genetic neuromuscular disorder causing physical limitations. Mutations in the SMN1 (survivor motor neuron 1) gene cause all types of spinal muscular atrophy. The number of copies that you have of the SMN2 gene alters the severity of the condition. Mutations in these genes can lead to a deficiency of survival motor neuron (SMN) protein. SMN protein is a critical molecule necessary for the health and function of motor neurons. These specialized nerve cells in the brain and spinal cord are responsible for controlling voluntary muscle movement, including essential functions like walking, speaking, swallowing, and breathing. When SMN protein is lacking, motor neurons progressively deteriorate, resulting in muscle weakness, atrophy (wasting), and a broad spectrum of physical limitations that vary in severity depending on disease type and age at onset. Some forms of the disease begin in infancy with profound impacts on the ability to sit or breathe independently, while others emerge later in childhood or adulthood with milder symptoms.
Despite being one of the most common inherited neuromuscular disorders, SMA remains a condition with significant unmet needs. Clinical research has been at the heart of this progress towards optimized therapies and understanding of long-term outcomes.
At the Neurology Rare Disease Center, we are dedicated to empowering patients and families to explore clinical trial opportunities that may offer access to cutting-edge therapies while contributing to scientific discovery that can benefit the broader SMA community, including underrepresented populations. Whether you are seeking information about eligibility, want to understand what to expect from trial participation, or are ready to take the next step in your care journey, our team is here to support you.
NCT07047144
A study to evaluate how Apitegromab works in subjects who are less than two years old and have Spinal Muscular Atrophy.
NCT07221669
Open-label study to assess the efficacy and safety of multiple doses of Salanersen (BIIB15) delivered intrathecally to treatment-naïve, presymptomatic infants with genetically diagnosed SMA.
NCT06436742
A Phase 2 study to assess the safety, tolerability, efficacy, pharmacokenitics, and immunogenecity of IV administration of ARGX-119 in participants aged five to less than 18 years with SMA.
Contact
Phone: (972) 982-7411
FAX: (972) 982-7610
Email: newpatient@neuromdcenter.com
Business Hours:
Monday – Friday
9AM- 5PM By Appointment Only
1651 Justin Rd.
Flower Mound, TX 75028
Content, including images, displayed on this website is protected by copyright laws.
Downloading, republication, retransmission or reproduction of content on this website is strictly prohibited. © NeuroMD. All Rights Reserved.